189 related articles for article (PubMed ID: 12957250)
1. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.
Nahum AE; Movsas B; Horwitz EM; Stobbe CC; Chapman JD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):391-401. PubMed ID: 12957250
[TBL] [Abstract][Full Text] [Related]
2. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
3. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
4. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
Fowler JF
Acta Oncol; 2005; 44(3):265-76. PubMed ID: 16076699
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data.
Wang JZ; Li XA; Mayr NA
Br J Radiol; 2006 Nov; 79(947):905-11. PubMed ID: 16885177
[TBL] [Abstract][Full Text] [Related]
6. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?
Wang JZ; Li XA; Yu CX; DiBiase SJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1101-8. PubMed ID: 14575842
[TBL] [Abstract][Full Text] [Related]
7. How low is the alpha/beta ratio for prostate cancer?
Wang JZ; Guerrero M; Li XA
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):194-203. PubMed ID: 12504054
[TBL] [Abstract][Full Text] [Related]
8. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT).
Wang JZ; Li XA; D'Souza WD; Stewart RD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):543-52. PubMed ID: 12957268
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy.
Pop LA; Millar WT; Visser AG; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872
[TBL] [Abstract][Full Text] [Related]
10. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
11. Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy.
Her EJ; Reynolds HM; Mears C; Williams S; Moorehouse C; Millar JL; Ebert MA; Haworth A
Phys Med Biol; 2018 Jun; 63(13):135011. PubMed ID: 29799812
[TBL] [Abstract][Full Text] [Related]
12. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer.
Lindsay PE; Moiseenko VV; Van Dyk J; Battista JJ
Phys Med Biol; 2003 Feb; 48(4):507-22. PubMed ID: 12630745
[TBL] [Abstract][Full Text] [Related]
13. Volume effects in the TCP for hypoxic and oxygenated tumors.
Chvetsov AV; Stewart RD; Kim M; Meyer J; Rengan R
Med Phys; 2020 Sep; 47(9):4626-4633. PubMed ID: 32452034
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.
Brenner DJ; Martinez AA; Edmundson GK; Mitchell C; Thames HD; Armour EP
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):6-13. PubMed ID: 11777617
[TBL] [Abstract][Full Text] [Related]
16. Is alpha/beta for prostate tumors really low?
Fowler J; Chappell R; Ritter M
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1021-31. PubMed ID: 11429230
[TBL] [Abstract][Full Text] [Related]
17. Tumor control probability (TCP) in prostate cancer: role of radiobiological parameters and radiation dose escalation.
Ahmad S; Vogds BJ; McKenna F; Vlachaki MT
J Xray Sci Technol; 2009; 17(4):347-54. PubMed ID: 19923690
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.
Carlson DJ; Keall PJ; Loo BW; Chen ZJ; Brown JM
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1188-95. PubMed ID: 21183291
[TBL] [Abstract][Full Text] [Related]
19. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
[TBL] [Abstract][Full Text] [Related]
20. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
